NFKB1 and systemic lupus erythematosus: As shown in Fig. 4c, the A2AAR agonist determined a marked reduction of LPS-stimulated NF-kB p65 subunit activation in nuclear extract from lymphocytes obtained from patients with SLE and healthy subjects, with a significantly greater effect in the former (see Table 3).